Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06892548 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 88 → 91 locations Collaborators: 2 to 1v17 Show 1 more changeShow less
    • Collaborators: 2 to 1

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 86 to 88v16
  3. Primary completion pushed from Aug 2027 to Sep 2028 Trial sites expanded: 76 → 86 locations · Completion pushed from Jun 2031 to May 2032v15 Show 2 more changesShow less
    • Trial sites expanded: 76 → 86 locations
    • Completion pushed from Jun 2031 to May 2032
  4. Trial sites expanded: 58 → 76 locationsv14
  5. Trial sites expanded: 52 → 58 locationsv13
Show 11 earlier versionsHide 11 earlier versions
  1. Study sites: 45 to 52v12
  2. Study sites: 38 to 45v11
  3. Study sites: 28 to 38v10
  4. Study sites: 20 to 28v9
  5. Study sites: 12 to 20v8
  6. Study sites: 9 to 12v7
  7. Study sites: 8 to 9v6
  8. Study sites: 6 to 8v5
  9. Study sites: 2 to 6v4
  10. Study sites: 1 to 2v3
  11. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Apr 2025 to May 2, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2025 to May 2, 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
BioNTech SE
49 trials monitored
See 3 trials at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).
Trial Details
NCT Number NCT06892548
Lead Sponsor BioNTech SE
Collaborators: DualityBio Inc.
Conditions Advanced Lung Cancer
Enrollment 594 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov